JC Partners files for regulatory review to acquire KDB Life Insurance Financial watchdog expected to complete review process by August
Translated by Ryu Ho-joung 공개 2021-06-22 08:25:50
이 기사는 2021년 06월 22일 08:15 thebell 에 표출된 기사입니다.
The last hurdle for JC Partners to acquire a troubled South Korean life insurance company is likely to clear in two months as the country’s financial watchdog begins regulatory review.The Seoul-based private equity firm filed paperwork with the Financial Supervisory Service (FSS) on Thursday to kick off a process to examine whether it is eligible to become the largest shareholder of KDB Life Insurance, industry sources said.
The regulatory review comes six months after JC Partners signed a deal to buy some 92% of the insurance company from the state-controlled Korea Development Bank in December. The evaluation process is expected to take around 60 days to complete, with a final decision likely to be made in August.
JC Partners’ acquisition of KDB Insurance has been under preliminary review for the past few months, through which the private equity firm produced a final draft for review by the FSS.
JC Partners is said to have paid careful attention to the composition of limited partners to get approval from the financial authorities, which are stricter toward a private equity firm’s acquisition of a financial services company.
JC Partners has completed financing for the acquisition. 200 billion won ($176.4 million), which was raised from Woori Bank and KDB, will be paid to purchase shares from existing shareholders. The firm will also inject 150 billion won into the insurance company.
It has reportedly yet to be determined whether JC Partners will invest more money in KDB Life Insurance to boost its capital base. An additional capital injection is likely to be decided depending on how the company will fare under JC Partners’ ownership.
JC Partners, if it gets the green light from the FSS, will likely focus on improving the company’s capital adequacy level. KDB Life Insurance had a risk-based capital ratio of 187% at the end of March, far below the industry average of 273.2%. (Reporting by Ar-rum Rho)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 경남제약 품는 휴마시스, 유통네트워크·진단키트 '시너지'
- [Company Watch]글로벌텍스프리, 프랑스 자회사 '적자 전환'
- [Red & Blue]'주목도 높아지는 폐배터리' 새빗켐, 침묵 깨고 반등
- [HLB '리보세라닙' 미국 진출기]시장 우려 불식 나선 진양곤, 갑자기 마련된 기자회견
- 효성화학 특수가스 사업부, '경영권 지분 매각'으로 선회
- 한양, 만기도래 회사채 '사모채'로 차환한다
- 동인기연, 'GS 출신' 30년 베테랑 전호철 상무 영입 '성장 방점'
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진